Sign In
Buy FULC
$3.22
+0.0800 (+2.55%)
At Close: Jun 03, 2026
Wall Street Analysts Believe Fulcrum Therapeutics (FULC) Could Rally 71.02%: Here's is How to Trade
10:55am, Wednesday, 21'st Aug 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 71% in Fulcrum Therapeutics (FULC). While the effectiveness of this highly sought-after metric is questionable,
CAMBRIDGE, Mass., Aug. 19, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve t
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 09'th Aug 2024
CAMBRIDGE, Mass., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives o
Fulcrum Therapeutics, Inc. (FULC) Is Up 7.55% in One Week: What You Should Know
01:01pm, Monday, 05'th Aug 2024
Does Fulcrum Therapeutics, Inc. (FULC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Fulcrum Therapeutics (FULC) Upgraded to Strong Buy: Here's What You Should Know
01:01pm, Monday, 05'th Aug 2024
Fulcrum Therapeutics (FULC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Does Fulcrum Therapeutics (FULC) Have the Potential to Rally 68.69% as Wall Street Analysts Expect?
11:01am, Monday, 05'th Aug 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 68.7% in Fulcrum Therapeutics (FULC). While the effectiveness of this highly sought-after metric is questionabl
New Strong Buy Stocks for August 5th
07:05am, Monday, 05'th Aug 2024
KGC, MCY, WGS, CHRW and FULC have been added to the Zacks Rank #1 (Strong Buy) List on August 5, 2023.
Fulcrum Therapeutics, Inc. (FULC) Q2 2024 Earnings Call Transcript
05:34pm, Wednesday, 31'st Jul 2024
Fulcrum Therapeutics, Inc. (NASDAQ:FULC ) Q2 2024 Results Conference Call July 31, 2024 8:00 AM ET Company Participants Alex Sapir - CEO and President Alan Musso - CFO Iain Fraser - SVP of Early Devel
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024
07:00am, Wednesday, 31'st Jul 2024
― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) by the end of October 2024 ―
Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET
08:00am, Wednesday, 24'th Jul 2024
CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to
Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter
08:16am, Tuesday, 16'th Jul 2024
As of July 16, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Wall Street Analysts See a 69.15% Upside in Fulcrum Therapeutics (FULC): Can the Stock Really Move This High?
10:56am, Wednesday, 15'th May 2024
The consensus price target hints at a 69.2% upside potential for Fulcrum Therapeutics (FULC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earni
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
07:00am, Monday, 13'th May 2024
― Entered into a collaboration and ex-U.S. license agreement with Sanofi for the development and commercialization of losmapimod ―
― Sanofi receives exclusive rights to commercialize losmapimod in all territories outside the U.S.; Fulcrum retains full U.S. commercialization rights ―
CAMBRIDGE, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to
